(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone and nabilone

(3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone has been researched along with nabilone in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Attali, A; Duursma, A; Lange, JH; Mulder, A; van Aken, HH; van der Neut, MA; van Vliet, BJ; Wals, HC; Zilaout, H	1
Buzard, DJ; Han, S; Jones, RM; Thatte, J	1

Reviews

1 review(s) available for (3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone and nabilone

Article	Year
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists. Journal of medicinal chemistry, 2013, Nov-14, Volume: 56, Issue:21 Topics: Animals; Drug Design; Humans; Ligands; Models, Molecular; Molecular Conformation; Receptor, Cannabinoid, CB2; Structure-Activity Relationship; Substrate Specificity	2013

Other Studies

1 other study(ies) available for (3r)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone and nabilone

Article	Year
Two distinct classes of novel pyrazolinecarboxamides as potent cannabinoid CB1 receptor agonists. Bioorganic & medicinal chemistry letters, 2010, Sep-01, Volume: 20, Issue:17 Topics: Pyrazoles; Receptor, Cannabinoid, CB1	2010